Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-14T17:08:25.270Z Has data issue: false hasContentIssue false

10 - Evidence-based pharmacotherapy of eating disorders

Published online by Cambridge University Press:  05 August 2012

By
Martine F. Flament ,
Hany Bissada  and
Wendy Spettigue
Edited by
Dan Stein ,
Bernard Lerer  and
Stephen M. Stahl
Dan Stein
Affiliation:
University of Cape Town
Bernard Lerer
Affiliation:
Hadassah-Hebrew Medical Centre
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

Eating disorders (EDs) are widespread, disabling, and often chronic psychiatric disorders. Anorexia nervosa (AN) and bulimia nervosa (BN) share amorbid preoccupation with weight and shape. This chapter reviews currently available evidence for efficacy and safety of pharmacotherapy in adults and children with EDs. It presents the pharmacotherapy for AN, BN, binge-eating disorder (BED), and night eating syndrome (NES). AN is a disease characterized by denial of illness, frequent treatment refusal, and noncompliance with pharmacological treatment due to fear of gaining weight. In the acute treatment of AN, weight gain is critical and often requires a combined approach including psychological support, nutritional rehabilitation, cognitive-behavioral treatment (CBT) and, for children and adolescents, family interventions. Large-scale well-designed trials should investigate combination of treatments or treatment augmentations, in order to target both eating-related symptoms and the underlying psychological and cognitive disturbances.

Keywords

antidepressantsantipsychoticsbipolar disorderquetiapinerelapse preventionlamotriginepharmacotherapyvalproate
Type
Chapter
Information
Essential Evidence-Based Psychopharmacology , pp. 190 - 213
Publisher: Cambridge University Press
Print publication year: 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×